Clinical Trial

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Name: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy — clinical trial record (NCT06056830)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CLARIFY

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

Protocol Amendment History 1 change

notable Trial sites expanded: 28 -> 31 locations 2026-05-15

Trial Details

NCT Number	NCT06056830
Lead Sponsor	Clarity Pharmaceuticals Ltd
Conditions	Prostate Cancer, Prostatic Neoplasms
Enrollment	383 participants
Start Date	2023-12-21
Primary Completion	2026-09 (estimated)
Study Completion	2026-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-14